AbbVie Inc.

ABBV

US00287Y1091

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 03:18:20 2024-04-25 pm EDT			5-day change	1st Jan Change
167 ^USD	-0.48%		+1.24%	+7.58%

05:07pm	AbbVie Says Rinvoq Shows Superiority Versus Dupixent in Atopic Dermatitis Trial Primary Endpoint	MT
12:11pm	Scholz promises support for pharma sector in Germany as Merck invests	RE

ABBVIE INC. : Termination of a Material Definitive Agreement (form 8-K)

February 14, 2020 at 06:06 pm EST

02-10

2020-02-11

id="From2020-02-102020-02-11_custom_Sec1.375SeniorNotesDue2024Member_exch_XNYS">

scheme="http://www.sec.gov/CIK">0001551152

dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec1.375SeniorNotesDue2024Member

dimension="dei:EntityListingsExchangeAxis">exch:XNYS


        2020-02-10
        2020-02-11id="From2020-02-102020-02-11_custom_Sec0.750SeniorNotesDue2027Member_exch_XNYS">


scheme="http://www.sec.gov/CIK">0001551152


dimension="us-gaap:StatementClassOfStockAxis">abbv:Sec0.750SeniorNotesDue2027Member
© Edgar Online, source Glimpses

Latest news about AbbVie Inc.

AbbVie Says Rinvoq Shows Superiority Versus Dupixent in Atopic Dermatitis Trial Primary Endpoint	11:07am	MT
Scholz promises support for pharma sector in Germany as Merck invests	06:11am	RE
US CDC warns of harmful reactions to fake Botox injections	Apr. 23	RE
Pfizer: new Emblaveo antibiotic approved in the EU	Apr. 22	CF
Sector Update: Health Care Stocks Advance Late Afternoon	Apr. 19	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 19	MT
Sector Update: Health Care	Apr. 19	MT
Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	Apr. 19	MT
Deutsche Bank Raises AbbVie's Price Target to $175 Form $170	Apr. 19	MT
Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	Apr. 19	MT
Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix...	Apr. 18
AbbVie Says Potential Treatment for Giant Cell Arteritis Met Endpoints in Phase 3 Study	Apr. 18	MT
AbbVie Study on Treatment for Giant Cell Arteritis Meets Primary Endpoint	Apr. 18	DJ
AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib Showed Positive Results in Patients with Giant Cell Arteritis	Apr. 18	CI
OSE: licensing agreement with AbbVie enters into force	Apr. 17	CF
OSE Immunotherapeutics Finalizes Drug License, Collaboration Deal With AbbVie	Apr. 17	MT
Medincell: share price rises following agreement with AbbVie	Apr. 17	CF
Medincell, AbbVie to Co-Develop Injectable Therapeutics	Apr. 16	DJ
AbbVie Says Phase 3 Interim Data Support Long-Term Efficacy, Safety of Migraine Drug	Apr. 12	MT
AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine	Apr. 12	CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	Apr. 08	RE
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 05	RE
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 04	RE
AbbVie Flags Hit to Q1 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook	Apr. 04	MT
US takes next step in Medicare drug price negotiations with pharma companies	Apr. 02	RE

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

167.8 USD

Average target price

184.1 USD

Spread / Average Target

+9.74%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+7.65%	297B
NOVO NORDISK A/S	+24.17%	562B
JOHNSON & JOHNSON	-6.16%	358B
MERCK & CO., INC.	+19.44%	322B
ASTRAZENECA PLC	+13.45%	219B
NOVARTIS AG	+6.04%	199B
ROCHE HOLDING AG	-10.51%	196B
PFIZER, INC.	-11.80%	149B
AMGEN INC.	-6.31%	146B
SANOFI	+2.07%	117B

Other Pharmaceuticals

AbbVie Inc.

Equities

ABBV

US00287Y1091

Pharmaceuticals

ABBVIE INC. : Termination of a Material Definitive Agreement (form 8-K)

Latest news about AbbVie Inc.

Chart AbbVie Inc.

Company Profile

Income Statement Evolution

Ratings for AbbVie Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals